Literature DB >> 22926854

2010 McDonald criteria for diagnosing pediatric multiple sclerosis.

Yair Sadaka1, Leonard H Verhey, Manohar M Shroff, Helen M Branson, Douglas L Arnold, Sridar Narayanan, John G Sled, Amit Bar-Or, A Dessa Sadovnick, Melissa McGowan, Ruth Ann Marrie, Brenda Banwell.   

Abstract

OBJECTIVE: The diagnosis of multiple sclerosis (MS) rests on confirmation of central nervous system inflammatory disease that is disseminated in space and time, as evidenced clinically or by magnetic resonance imaging (MRI). The 2010 McDonald criteria simplified MRI requirements, and newly proposed that the criteria are also suitable for the diagnosis of pediatric MS.
METHODS: In a national prospective incident cohort study of children with acute demyelination observed for a minimum of 24 months, baseline and serial clinical and MRI examinations were used to retrospectively evaluate the 2010 and 2005 McDonald criteria using clinically relapsing disease as the gold standard.
RESULTS: Of 212 eligible participants, 34 experienced 2 or more clinical attacks, 58 met the 2010 criteria, and 42 met 2005 McDonald criteria. The 2010 criteria demonstrated high sensitivity (100%), specificity (86%), positive predictive value (76%), and negative predictive value (100%) for children older than 11 years with non-acute disseminated encephalomyelitis (ADEM) presentations, as did the 2005 McDonald criteria. In younger children with a non-ADEM presentation, PPV of the 2010 criteria was only 55%. None of the 50 children with ADEM met clinical criteria for MS, but 10 met 2010 and 4 met 2005 criteria.
INTERPRETATION: Both 2005 and 2010 McDonald criteria identify children with relapsing-remitting MS, although caution is suggested when applying these criteria in younger children. The 2010 McDonald criteria are simple and enable an early diagnosis of MS, but are not suited for application in the context of ADEM-like presentations.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Year:  2012        PMID: 22926854     DOI: 10.1002/ana.23575

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

Review 2.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 3.  Longitudinally extensive myelopathy in children.

Authors:  Danielle Eckart Sorte; Andrea Poretti; Scott D Newsome; Eugen Boltshauser; Thierry A G M Huisman; Izlem Izbudak
Journal:  Pediatr Radiol       Date:  2015-01-31

Review 4.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

5.  Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.

Authors:  Ana Cristina Wing; Joana Hygino; Thais B Ferreira; Taissa M Kasahara; Priscila O Barros; Priscila M Sacramento; Regis M Andrade; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Claudia Cristina Vasconcelos; Regina Alvarenga; Cleonice A M Bento
Journal:  Immunology       Date:  2015-12-02       Impact factor: 7.397

Review 6.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 7.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

9.  No evidence for impairment of venous hemodynamics in children or young adults with pediatric-onset multiple sclerosis.

Authors:  S Laughlin; C K Macgowan; J Traubici; K Chan; S Khan; D L Arnold; R A Marrie; B Banwell
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-18       Impact factor: 3.825

10.  Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.

Authors:  Leonard H Verhey; Alessio Signori; Douglas L Arnold; Amit Bar-Or; A Dessa Sadovnick; Ruth Ann Marrie; Brenda Banwell; Maria Pia Sormani
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.